{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:15:14Z","timestamp":1707524114366},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,2]]},"DOI":"10.7759\/cureus.9525","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T18:54:01Z","timestamp":1596394441000},"source":"Crossref","is-referenced-by-count":0,"title":["Intrathecal Access Through Suboccipital Port in Patients With Spinal Muscular Atrophy and Complex Spines: Case Series and Technical Note"],"prefix":"10.7759","author":[{"given":"Diem Kieu","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaibhavi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G","family":"Muhonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180330","article-title":"Perspectives on Spinraza (nusinersen) treatment study: views of individuals and parents of children diagnosed with spinal muscular atrophy","volume":"6","author":"Pacione M","year":"2019","unstructured":"Pacione M, Siskind CE, Day JW, Tabor HK. Perspectives on Spinraza (nusinersen) treatment study: views of individuals and parents of children diagnosed with spinal muscular atrophy. J Neuromuscul Dis. 2019, 6:119-131. 10.3233\/JND-180330","journal-title":"J Neuromuscul Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2309\/108300800775897953","article-title":"A randomized, prospective trial of conventional vascular ports vs. the vortex \u201cclear-flow\u201d reservoir port in adult oncology patients","volume":"5","author":"Stevens B","year":"2000","unstructured":"Stevens B, Barton SE, Brechbill M, Moenter S, Piel AL, Shankle D. A randomized, prospective trial of conventional vascular ports vs. the vortex \u201cclear-flow\u201d reservoir port in adult oncology patients. J Vasc Access Devices. 2000, 5:37-40. 10.2309\/108300800775897953","journal-title":"J Vasc Access Devices"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review","volume":"12","author":"Verhaart IEC","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al.. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017, 12:124. 10.1186\/s13023-017-0671-8","journal-title":"Orphanet J Rare Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel RS","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, et al.. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017, 377:1723-1732. 10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn MR","year":"2008","unstructured":"Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008, 371:2120-2133. 10.1016\/S0140-6736(08)60921-6","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.08.002","article-title":"A positive modifier of spinal muscular atrophy in the SMN2 gene","volume":"85","author":"Prior TW","year":"2009","unstructured":"Prior TW, Krainer AR, Hua Y, et al.. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009, 85:408-413. 10.1016\/j.ajhg.2009.08.002","journal-title":"Am J Hum Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1515\/tnsci-2017-0001","article-title":"ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy","volume":"8","author":"Ottesen EW","year":"2017","unstructured":"Ottesen EW. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Transl Neurosci. 2017, 8:1-6. 10.1515\/tnsci-2017-0001","journal-title":"Transl Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell JR","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al.. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017, 377:1713-1722. 10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri E","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al.. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018, 378:625-635. 10.1056\/NEJMoa1710504","journal-title":"N Engl J Med"},{"key":"ref10","article-title":"Motor neuron disease: positive trial results published for ground-breaking SMA therapies","volume":"14","author":"Ridler C","year":"2018","unstructured":"Ridler C. Motor neuron disease: positive trial results published for ground-breaking SMA therapies. Nat Rev Neurol. 2018, 14:1. https:\/\/doi.org\/10.1038\/nrneurol.2017.163","journal-title":"Nat Rev Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2018.24","article-title":"Motor neuron disease: benefits of nusinersen extend to later-onset SMA","volume":"14","author":"Wood H","year":"2018","unstructured":"Wood H. Motor neuron disease: benefits of nusinersen extend to later-onset SMA. Nat Rev Neurol. 2018, 14:196. 10.1038\/nrneurol.2018.24","journal-title":"Nat Rev Neurol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419887616","article-title":"Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy","volume":"13","author":"Cordts I","year":"2020","unstructured":"Cordts I, Lingor P, Friedrich B, et al.. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. 2020, 13:10.1177\/1756286419887616","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/36755-intrathecal-access-through-suboccipital-port-in-patients-with-spinal-muscular-atrophy-and-complex-spines-case-series-and-technical-note","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:23:51Z","timestamp":1707506631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/36755-intrathecal-access-through-suboccipital-port-in-patients-with-spinal-muscular-atrophy-and-complex-spines-case-series-and-technical-note"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,2]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.9525","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,2]]}}}